• Zealand Pharma reported nine-month 2026 profit of DKK 3.47 billion and revenue of DKK 4.53 billion.
• Cash position fell 11% from December 31, 2025, to DKK 13.51 billion at September 30, 2026.
• Petrelintide entered Phase 3 development with Roche, while Boehringer Ingelheim plans global obesity regulatory submissions for survodutide in 2027.
• The 2026 revenue outlook remained unchanged at DKK 4.5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120100PRIMZONEFULLFEED1001303125) on November 12, 2026, and is solely responsible for the information contained therein.